{
    "Trade/Device Name(s)": [
        "ARK Fentanyl II Assay"
    ],
    "Submitter Information": "ARK Diagnostics, Inc.",
    "510(k) Number": "K200197",
    "Predicate Device Reference 510(k) Number(s)": [
        "K180427"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "February 26, 2020",
    "Summary Letter Received Date": "January 27, 2020",
    "Submission Date": "January 24, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Fentanyl"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzer",
        "Beckman Coulter AU680"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay",
        "Immunoassay"
    ],
    "Methodologies": [
        "Enzyme immunoassay (EIA)",
        "Qualitative drug screening"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ARK Fentanyl II Assay, a qualitative enzyme immunoassay for detection of fentanyl in urine using automated clinical chemistry analyzers.",
    "Indications for Use Summary": "For qualitative detection of fentanyl in human urine at a cutoff concentration of 1.0 ng/mL in laboratories with automated clinical chemistry analyzers; provides preliminary results requiring confirmation by alternative methods.",
    "fda_folder": "Toxicology"
}